Table 1. Questions in the context of the newly identified anti-inflammatory activity of lactocepin.
| Summary of open questions | ||||||
|---|---|---|---|---|---|---|
| |
|
|
|
|
|
|
| |
Intestinal prtP-expression? |
|
|
|
||
| |
‒ localization (luminal, mucosal, intestinal compartments) |
|
||||
| |
‒ expression level (health, inflammation, probiotic supplementation) |
|||||
| |
|
|
|
|
|
|
| |
Substrate specificity of prtP? |
|
|
|
||
| |
‒ substrate binding residues, folding |
|
|
|
||
| |
‒ lactobacillus vs. lactococcus prtP |
|
|
|
||
| |
‒ related CEPs (prtB, prtH, prtR, prtS) |
|
|
|
||
| |
|
|
|
|
|
|
| |
Therapeutical relevance of isolated prtP-encoded lactocepin? |
|
||||
| |
‒ oral application in IBD |
|
|
|
|
|
| |
‒ topical application in inflammatory skin diseases |
|
|
|||
| |
‒ injections (i.v., joints, subcutaneous) |
|
|
|||